Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease

Pediatrics International

Volumn 52, Issue 5, 2010, Pages 754-761

  Sbrocchi, Anne Marie ^a   Forget, Sylviane ^b   Laforte, Diane ^c   Azouz, E Michel ^d   Rodd, Celia ^a  

^a Division of Endocrinology   (United States)

^b Division of Gastroenterology   (United States)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

bisphosphonates; C telopeptide; dual energy X ray absorptiometry; fractures; osteopenia; pediatric Crohn's disease

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; ZOLEDRONIC ACID;

ADOLESCENT; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; FEVER; HUMAN; LUMBAR SPINE; NAUSEA; OSTEOPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADOLESCENT; ANALYSIS OF VARIANCE; BONE DENSITY; BONE DISEASES, METABOLIC; CHILD; CROHN DISEASE; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; PROSPECTIVE STUDIES; REFERENCE VALUES; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957363353     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2010.03174.x     Document Type: Article

References (46)

1. Baim S, Leonard MB, Bianchi ML et al. Official positions of the international society for clinical densitometry and executive summary of the 2007 ISCD pediatric position development conference. J. Clin. Densitom. 2008 11 : 6 21. (Pubitemid 351602184)
2. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol. Clin. North Am. 1999 28 : 445 458.
3. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 1998 42 : 188 194.
4. Cowan FJ, Parker DR, Jenkins HR. Osteopenia in Crohn's disease. Arch. Dis. Child. 1995 73 : 255 256.
5. Semeao EJ, Jawad AF, Zemel BS, Neiswender KM, Piccoli DA, Stallings VA. Bone mineral density in children and young adults with Crohn's disease. Inflamm. Bowel Dis. 1999 5 : 161 166.
6. Mauro M, Armstrong D. Juvenile onset of Crohn's disease: A risk factor for reduced lumbar bone mass in premenopausal women. Bone 2007 40 : 1290 1293.
7. Slemenda CW, Reister TK, Hui SL, Miller JZ, Christian JC, Johnston CC Jr. Influences on skeletal mineralization in children and adolescents: Evidence for varying effects of sexual maturation and physical activity. J. Pediatr. 1994 125 : 201 207.
8. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997 112 : 1710 1713.
9. Walther F, Fusch C, Radke M, Beckert S, Findeisen A. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J. Pediatr. Gastroenterol. Nutr. 2006 43 : 42 51.
10. Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998 114 : 902 911.
11. Sylvester FA, Wyzga N, Hyams JS et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm. Bowel. Dis. 2007 13 : 42 50.
12. Bechtold S, Alberer M, Arenz T et al. Reduced muscle mass and bone size in pediatric patients with inflammatory bowel disease. Inflamm. Bowel. Dis. 16 : 216 225.
13. Benchimol EI, Ward LM, Gallagher JC et al. Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2007 45 : 538 545.
14. Bartram SA, Peaston RT, Rawlings DJ et al. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J. Gastroenterol. 2006 12 : 5680 5686.
15. Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment. Pharmacol. Ther. 2003 18 : 1121 1127.
16. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease [see comment]. Gastroenterology 2000 119 : 639 646.
17. Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease [see comment]. Am. J. Gastroenterol. 2006 101 : 119 123.
18. Ward L, Tricco AC, Phuong P et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst. Rev. 2007. doi: 10.1002/14651858.CD005324.pub2. (Pubitemid 351805168)
19. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [see comment]. N. Engl. J. Med. 2007 356 : 1809 1822.
20. Allan RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio VW. Inflammatory Bowel Diseases, 3rd edn. Churchill-Livingstone, New York, 1997.
21. Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density [see comment]. N. Engl. J. Med. 2002 346 : 653 661. (Pubitemid 34815869)
22. Musgrave KO, Giambalvo L, Leclerc HL, Cook RA, Rosen CJ. Validation of a quantitative food frequency questionnaire for rapid assessment of dietary calcium intake. J. Am. Diet. Assoc. 1989 89 : 1484 1488.
23. Punthakee Z, Legault L, Polychronakos C. Prednisolone in the treatment of adrenal insufficiency: A re-evaluation of relative potency. J. Pediatr. 2003 143 : 402 405.
24. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM et al. CDC growth charts: United States. Adv. Data. 2000 1 27.
25. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch. Dis. Child. 1976 51 : 170 179.
26. Hyams JS, Ferry GD, Mandel FS et al. Development and validation of a pediatric Crohn's disease activity index. J. Pediatr. Gastroenterol. Nutr. 1991 12 : 439 447.
27. Salle BL, Braillon P, Glorieux FH, Brunet J, Cavero E, Meunier PJ. Lumbar bone mineral content measured by dual energy X-ray absorptiometry in newborns and infants. Acta Paediatr. 1992 81 : 953 958.
28. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner. Res. 1992 7 : 137 145.
29. Faulkner RA, Bailey DA, Drinkwater DT, McKay HA, Arnold C, Wilkinson AA. Bone densitometry in Canadian children 8-17 years of age. Calcif. Tissue Int. 1996 59 : 344 351.
30. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 1993 8 : 1137 1148.
31. Zacharin M, O'Sullivan M. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J. Pediatr. 2000 137 : 403 409.
32. Pinheiro J, Bates DM. Mixed-Effects Models in S and S-PLUS. Springer, New York, 2000.
33. Faulkner RA, Bailey DA, Drinkwater DT, Wilkinson AA, Houston CS, McKay HA. Regional and total body bone mineral content, bone mineral density, and total body tissue composition in children 8-16 years of age. Calcif. Tissue Int. 1993 53 : 7 12.
34. van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM. Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults. Arch. Dis. Child. 2002 87 : 341 347, discussion 41-7.
35. Molgaard C, Thomsen BL, Prentice A, Cole TJ, Michaelsen KF. Whole body bone mineral content in healthy children and adolescents. Arch. Dis. Child. 1997 76 : 9 15.
36. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture [see comment]. N. Engl. J. Med. 2007 357 : 1799 1809.
37. Kopterides P, Pikazis D, Koufos C. Successful treatment of SAPHO syndrome with zoledronic acid. Arthritis Rheum. 2004 50 : 2970 2973.
38. Hogler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. J. Pediatr. 2004 145 : 701 704.
39. Souza SC, Borges CT, Jorgetti V, Pereira RM. The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in juvenile systemic lupus erythematosus. Rev. Hosp. Clin. Fac. Med. Sao Paulo 2004 59 : 302 305.
40. Munns CF, Rajab MH, Hong J et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone 2007 41 : 366 370.
41. Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome [see comment]. N. Engl. J. Med. 2004 351 : 868 875.
42. Reffitt DM, Meenan J, Sanderson JD, Jugdaohsingh R, Powell JJ, Thompson RP. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2003 15 : 1267 1273.
43. Tonino RP, Meunier PJ, Emkey R et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group [see comment]. J. Clin. Endocrinol. Metab. 2000 85 : 3109 3115.
44. Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos. Int. 2000 11 : 281 294.
45. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease [see comment]. Gastroenterology 2000 119 : 895 902.
46. Bachrach LK, Ward LM. Clinical review 1: Bisphosphonate use in childhood osteoporosis. J. Clin. Endocrinol. Metab. 2009 94 : 400 409.